Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
Previous Symbol
CUSIPN/A
Phone44-0-12-3544-2780
Debt
Debt-to-Equity RatioN/A
Current Ratio2.23
Quick Ratio4.86
Price-To-Earnings
Trailing P/E Ratio-11.07
Forward P/E Ratio-15.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$103.08 million
Price / Sales3.86
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book5.44
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-12.51%
Return on Equity-41.15%
Return on Assets-24.11%
Miscellaneous
Employees457
Outstanding Shares26,360,000
Market Cap$409.51 million
OptionableNot Optionable
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Friday, November, 9th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.14. The firm had revenue of $16.10 million for the quarter, compared to the consensus estimate of $33.60 million. Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The business's revenue was up 7.3% on a year-over-year basis. During the same period last year, the company posted ($0.70) EPS. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
3 analysts have issued 1 year price targets for Oxford Immunotec Global's stock. Their predictions range from $15.00 to $19.00. On average, they anticipate Oxford Immunotec Global's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.
What is the consensus analysts' recommendation for Oxford Immunotec Global?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.
Has Oxford Immunotec Global been receiving favorable news coverage?
Press coverage about OXFD stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Fluoropharma Medical (FPMI) and BG Medicine (BGMD).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
- Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
Who are Oxford Immunotec Global's major shareholders?
Oxford Immunotec Global's stock is owned by many different of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (6.14%), BlackRock Inc. (5.04%), Wasatch Advisors Inc. (3.25%), Grandeur Peak Global Advisors LLC (2.38%), Stonepine Capital Management LLC (0.87%) and Bellevue Group AG (0.85%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.
Which institutional investors are selling Oxford Immunotec Global stock?
OXFD stock was sold by a variety of institutional investors in the last quarter, including Grandeur Peak Global Advisors LLC, Birchview Capital LP, Keybank National Association OH, Jane Street Group LLC, Wasatch Advisors Inc., Rhumbline Advisers, Russell Investments Group Ltd. and C WorldWide Group Holding A S. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.
Which institutional investors are buying Oxford Immunotec Global stock?
OXFD stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Bellevue Group AG, Renaissance Technologies LLC, FMR LLC, United Services Automobile Association and Hound Partners LLC. View Insider Buying and Selling for Oxford Immunotec Global.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $15.08.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $409.51 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.
What is Oxford Immunotec Global's official website?
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
